BDX Stock Recent News
BDX LATEST HEADLINES
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Becton, Dickinson and Company (NYSE: BDX). The settlement provides for a fund of $85,000,000 to benefit class members.
NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Becton, Dickinson and Company (NYSE: BDX). The settlement provides for a fund of $85,000,000 to benefit class members.
BD's (BDX) latest agreement is likely to unlock new future value-creation opportunities and expand its portfolio of smart connected care solutions.
NEW YORK, NY / ACCESSWIRE / June 4, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Becton, Dickinson and Company (NYSE: BDX). The settlement provides for a fund of $85,000,000 to benefit class members.
Shares of Becton Dickinson (BDX) advanced close to 3% Monday as the maker of syringes and other medical devices announced it was buying the Critical Care product unit of Edwards Lifesciences (EW) for $4.2 billion in cash.
BD's (BDX) robust product portfolio raises optimism about the stock.
The buyer intends to fund deal with a combination of $1 billion in cash and $3.2 billion of new debt in a transaction that is one of its largest of many.
Edwards Lifesciences on Monday said it has agreed to sell its Critical Care products unit to Becton Dickinson in an all-cash transaction valued at $4.2 billion.
Shares of Edwards Lifesciences Corp. EW, -1.14% rallied 3% in premarket trading Monday, after the company announced an agreement to sell its critical care product group to Becton Dickinson & Co. BDX, +2.29% in a cash deal valued at $4.2 billion. Edwards said it plans to use the proceeds from the sale to fund investments for growth, such as in technologies for technologies for aortic, mitral, tricuspid and pulmonic patients, and in therapeutic areas for interventional heart failure.
IRVINE, CA--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company) (NYSE: BDX), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care. Edwards will use the after-tax cash proceeds to fund strategic growth investments. The sale enhances Edwards' balance sheet flexibilit.